Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Coya Therapeutics, Inc. - Common Stock (NQ: COYA )

4.060 +0.035 (+0.87%)
Streaming Delayed Price Updated: 3:58 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 12,006
Open 4.000
Bid (Size) 4.060 (2)
Ask (Size) 4.150 (4)
Prev. Close 4.025
Today's Range 3.937 - 4.199
52wk Range 3.685 - 5.670
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
By David Willey, Benzinga 
Via TheNewswire.com
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is a Major Moment For Drug Development 
Via News Direct

Performance

YTD
-12.69%
-12.69%
1 Month
+1.25%
+1.25%
3 Month
-11.16%
-11.16%
6 Month
-11.16%
-11.16%
1 Year
-11.16%
-11.16%

More News

Read More
Coya Therapeutics, Inc. to Present at the Virtual Investor Summit on Wednesday, March 29, 2023, at 11:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics Reveals Proof-of-Concept Data From Small Study With ALS Patients
Via Benzinga
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via TheNewswire.com
Topics Death
Exposures Death
Coya Therapeutics’ COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via News Direct
Topics Death
Exposures Death
Coya Therapeutics Enters First-Of-Its-Kind Partnership With Multi-Billion Dollar Drug Company — Why This Is A Major Moment For Drug Development
Via Benzinga
Coya Therapeutics' COYA 302 Treating ALS Proves Effective In Proof-Of-Concept Academic Clinical Study
Via Benzinga
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via News Direct
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy’s Laboratories To License and Commercialize COYA 302
Via TheNewswire.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Reminder: Coya Therapeutics to Host Conference Call Presenting Positive Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) Today at 8:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics, Inc. Announces Positive Results from a Proof-of-Concept Academic Clinical Study for COYA 302 in Amyotrophic Lateral Sclerosis (ALS)
From Coya Therapeutics, Inc.
Via Business Wire
Houston-Based Coya Therapeutics Partners With Multi-Billion Dollar Global Drug Company Dr. Reddy's Laboratories To License And Commercialize COYA 302
Via Benzinga
Coya Therapeutics, Inc. Announces an Agreement with Dr. Reddy’s Laboratories, Ltd. to License its proposed biosimilar Abatacept for the Development and Commercialization of COYA 302 for the Treatment of Neurodegenerative Diseases
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics to Host Conference Call Presenting Clinical Data of COYA 302 in Patients with Amyotrophic Lateral Sclerosis (ALS) on March 21, 2023, at 8:00am ET
From Coya Therapeutics, Inc.
Via Business Wire
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
Via TheNewswire.com
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine’s Next Frontier?
Via News Direct
This Company Is Focused on Treg-Enhancing Therapies - Could This Be Medicine's Next Frontier?
Via Benzinga
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Via TheNewswire.com
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Via News Direct
Houston-Based Coya Therapeutics To Present Results From ALS Clinical Study Data For Its Investigational Biologic Combination at the 2023 MDA Clinical & Scientific Conference in Dallas
Via Benzinga
Coya Therapeutics to Present ALS Clinical Study Data for its Investigational Biologic Combination at the 2023 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference.
From Coya Therapeutics, Inc.
Via Business Wire
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
Via News Direct
Coya Therapeutics’ Expansion Of Exclusive Worldwide Licensing Agreement With ARscience Biotherapeutics Could Have Outsized Impact On Neurodegenerative And Autoimmune Diseases Treatments
Via TheNewswire.com
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.